Monte Rosa Therapeutics develops clinical-stage molecular glue degrader medicines using an AI-guided discovery engine targeting undruggable proteins.
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines. Its work targets proteins that are considered undruggable or inadequately drugged by conventional approaches, in pursuit of treatments for serious diseases. The company is headquartered in Boston, Massachusetts, with a presence in Basel, Switzerland.
Central to the company's approach is the QuEEN Discovery Engine (Quantitative and Engineered Elimination of Neosubstrates), an AI-guided platform that combines diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design molecular glue degraders. The underlying technical disciplines span molecular glue degrader chemistry, artificial intelligence, structural biology, proteomics and protein degradation.
Monte Rosa reports multiple MGD programs advancing through a clinical-stage pipeline across a wide-ranging, differentiated target space and multiple therapeutic areas. The company describes its objective as precision in targeting proteins with unprecedented specificity, and frames its mission as "Degrading Proteins, Making Medicines".
